Is the Options Market Predicting a Spike in Holley Stock? — Neutral
HLLY Zacks Investment Research — January 12, 2026Investors need to pay close attention to Holley stock based on the movements in the options market lately.
Is Home Depot Stock Best Positioned If Rates Ease in 2026? — Positive
HD Zacks Investment Research — January 12, 2026HD is gearing up for a 2026 housing rebound with Pro-focused tools and supply-chain upgrades to scale fast.
Zuckerberg spoke about the need for more “masculine energy” in corporate America, which he said had become “culturally neutered” in an episode of Joe Rogan's podcast last year—comments that were widely seen as targeting inclusivity initiatives by former Chief Operating Officer Sheryl Sandberg. “I think having a culture that celebrates the aggression a bit more has its own merits that are really positive,” he said.
Paramount Launches Proxy Fight For Control Of Warner Bros. Discovery — Negative
WBD Forbes — January 12, 2026Paramount said Monday it would push forward with its hostile bid for Warner Bros. Discovery by nominating directors to the WBD board that would engage with Paramount's offer, while also filing a lawsuit against the company to force it to disclose information about Netflix's offer.
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy — Neutral
BIIB GlobeNewsWire — January 12, 2026CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases.2 The SPINRAZA European Union marketing authorization has been updated to include the high dose regimen. The new high dose regimen comprises a more rapid loading phase, two 50 mg loading doses …
EXL named a Leader in five quadrants in ISG Provider Lens™ Insurance Services Global Report — Neutral
EXLS GlobeNewsWire — January 12, 2026NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, announced it has been recognized as a Leader in five quadrants in the ISG Provider Lens™ Insurance Services 2025 report. These include both service specialist capabilities, Life & Retirement and Property & Casualty, as well as the newly introduced categories for GenAI, Agentic AI and Global Capability Centers. This strong positioning highlights EXL's broad, end-to-end impact across the insurance value chain and its ability to apply next-generation intelligence at scale.
GeneDx Partners With Komodo Health to Advance Rare Disease Research — Positive
WGS Zacks Investment Research — January 12, 2026WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.
CRWD to Acquire SGNL: Is Identity Security the Next Growth Pillar? — Positive
CRWD Zacks Investment Research — January 12, 2026CrowdStrike agrees to acquire SGNL to boost identity security for AI-driven enterprises, adding real-time, risk-based access controls to the Falcon platform.
Hims & Hers Expands Platform-Led Access to Provider-Directed Care — Positive
HIMS Zacks Investment Research — January 12, 2026HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.
AP Upgraded to Outperform on Exits, Tariff Pass-Through & ALP — Positive
AP Zacks Investment Research — January 12, 2026Ampco-Pittsburgh's upgrade to Outperform reflects tariff pass-throughs, strategic exits, and ALP-driven growth at undervalued levels.
Thryv Holdings: Ignore Near-Term Lumps And Buy For Deep Value — Neutral
THRY Seeking Alpha — January 12, 2026Thryv Holdings is a compelling small-cap value play, transitioning from Yellow Pages to a recurring SaaS business with >30% SaaS growth. THRY's SaaS segment now comprises 58% of revenue, with organic growth at 14% and adjusted EBITDA margin near 20%. Despite a 60% stock decline, THRY trades at just 3.3x EV/FY25 adjusted EBITDA, offering deep value amid market pessimism.
This Stock Has Already Doubled in 2026, but Is It a Buy? — Positive
CRML 24/7 Wall Street — January 12, 2026Critical Metals ( NASDAQ:CRML ) has surged 115% so far in 2026, and the year is not even two weeks old yet.
SPECTRUM OPENS APPLICATIONS FOR SIXTH CLASS OF SPECTRUM SCHOLARS — Neutral
CHTR PRNewsWire — January 12, 2026$300,000 in Scholarships to Be Awarded to 15 College Students, Paired with Internship and Two-Year Professional Development Program Key Takeaways Spectrum will award 15 students with $20,000 each, raising its total investment in Spectrum Scholars to more than $2 million since 2020. Students gain access to professional development and a paid Spectrum internship.
Accelsius Closes $65 Million Series B Funding Led by Johnson Controls; Legrand Joining Round to Scale Liquid Cooling for Gigawatt-Class AI Factories — Neutral
INV Business Wire — January 12, 2026AUSTIN, Texas--(BUSINESS WIRE)---- $INV #liquidcooling--Accelsius announces its closed Series B funding round.
The Greenbrier Companies, Inc. receives a Sell rating due to cyclical headwinds, declining core manufacturing, and reliance on non-recurring earnings sources. Recent GBX EPS and revenue beats are driven by asset sales and resilient leasing, not sustainable improvements in GBX's core business fundamentals. Manufacturing gross margin fell to 11.0% from 15.7% amid a 19% revenue decline, with order backlog flat and no clear sign of cyclical recovery.
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% — Positive
VRCA Zacks Investment Research — January 12, 2026The mean of analysts' price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Sunrun (RUN) Could Rally 28.3%: Here's is How to Trade — Positive
RUN Zacks Investment Research — January 12, 2026The mean of analysts' price targets for Sunrun (RUN) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cybersecurity Stock Pops on Rare Double Upgrade — Positive
AKAM Schaeffers Research — January 12, 2026Shares of cloud computing name Akamai Technologies Inc (NASDAQ:AKAM) were last seen up 5.6% to trade at $93.09, after a rare double upgrade from Morgan Stanley to "overweight" from "underweight.
NuScale Power Plunges 54% in 3 Months: Time to Hold Tight or Exit? — Negative
SMR Zacks Investment Research — January 12, 2026SMR shares plunge 54.4% over the past three months as execution risks, long timelines and rich valuation pressure NuScale Power's nuclear growth plans.
Coca-Cola's Innovation Pipeline: Catalyst for Volume Acceleration? — Positive
KO Zacks Investment Research — January 12, 2026KO leans on product, digital and sustainability innovation as volumes soften, betting zero-sugar, hydration and RTD coffee to steady growth.
